On September 28, 2026, Imunon, Inc. entered into an Exchange Agreement with Streeterville Capital, LLC to exchange $1,200,000 of principal plus accrued interest from its Secured Promissory Note A-1 for 120 shares of newly designated Series B Preferred Stock at a price of $10,000 per share. The company simultaneously filed a Certificate of Designation with the Delaware Secretary of State authorizing 200 shares of Series B Preferred Stock with a stated value of $12,000 and an annual preferred return of 8%, payable in cash or additional stock. These securities carry no voting rights except for matters adversely affecting their preferences, and the company retains optional redemption rights at 110% of the liquidation amount. Imunon, Inc. operates in the biotechnology industry, focusing on cancer immunotherapy.
